PHILADELPHIA — Researchers at the Perelman School of Medicine at the University of Pennsylvania will receive $7.3 million over the next five years from the National Cancer Institute (NCI) to find new ways to treat esophageal cancer. This grant is a renewal of an NIH /NCI program funded over the last 10 years and is the only program of its kind funded by NCI for esophageal cancer.
“We are excited about this renewal, and it builds upon success in generating novel three-dimensional organ-like culture models, mouse models, and identifying key genes with clinical outcomes,” says Anil K. Rustgi, MD, former employee and the T. Grier Miller Professor of Medicine and Genetics and chief of the Gastroenterology Division, who is the overall principal investigator on the grant. “We have several candidate genes and pathways that serve as new and innovative targets for esophageal cancer, which we believe have implications in head and neck cancer as well as lung cancer.”
Continued research for esophageal cancer is critical for prolonging patient survival, especially since this type of cancer becomes prevalent in its later stages and patients often have a poor prognosis and reduced response to traditional chemoradiation therapy. Esophageal cancer is a common cancer worldwide and esophageal adenocarcinoma, one of two subtypes, has the fastest rate of increase of any cancer in the US. Rustgi presented to a Congressional Caucus in June 2014 on the Recalcitrant Cancer Research Act passed in 2013, of which esophageal cancer is one.
Three projects are the cornerstone of the grant:
Project One (Anil K. Rustgi, MD, Project Leader) will focus on the biological roles of the cooperation between p120-catenin and p53 tumor suppressor genes in the formation of esophageal tumor cells, as well as the interplay of these tumor cells with other proteins in the tumor microenvironment.
Project Two (J. Alan Diehl, PhD, Project Leader) elucidates the manner in which the protein cyclin D1 is regulated and defines the role of Fbx4 mutations in initiation of esophageal cancer. These findings will be developed into therapies that target cyclin D1/CDK4 kinase, and key downstream molecules.
Project Three (Kwok-Kin Wong, MD, PhD, and Adam Bass, MD, Dana-Farber Cancer Institute, Project Leaders) looks at genomic amplifications of genes encoding ERBB-family kinase proteins and cell-cycle mediators in esophageal cancers. These will serve as biomarkers to guide the use of targeted inhibitors and to test therapeutics in genomically defined models to identify optimal agents and rational combinations of targeted agents.
The projects are further supported by core facilities designed to provide esophageal cancer-specific services for collaborative research, and bring together a host of labs on the Penn campus, including those of Hiroshi Nakagawa, John Lynch, Jonathan Katz, Sunil Singhal, Devraj Basu, Meenhard Herlyn, and Marcia Brose.
The NCI funded this work under grant #P01-CA098101.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.